330 results about "Immunoconjugate" patented technology

This disclosure relates to dimeric immunoconjugates for use in treating cancer generally and to dimeric immunoconjugates that bind human sperm protein 17 (Sp17) specifically. A dimeric immunoconjugate of this disclosure generally comprises a first monomeric antibody that carries a first payload and a second monomeric antibody that carries a second payload, wherein the first payload and the second payload are different. Such dimeric immunoconjugates advantageously allow the simultaneous delivery of two chemotherapeutics to a cancer cell, which allows for synergistic antineoplastic activity.

The present application relates to an antibody capable of specifically binding to c-Met or antigen-binding fragment thereof, and an immunoconjugate, a pharmaceutical composition and a multispecific molecule comprising the same. The present application further relates to the use of the antibody specifically binding to c-Met or an antigen-binding fragment thereof and the multispecific molecule. Compared with the control antibody, the bispecific antibody or defucosylated bispecific antibody of the present application can block HGF-dependent TKI resistance; block the proliferation and migration of tumor cells induced by HGF, induce ADCC effect, and inhibit tumor growth in vivo.

Described herein are novel linkers for use with immunoconjugates to connect a targeting moiety to a radiochelator moiety without impairing the functionality of either. The linkers of the invention may provide a stable linkage in circulation, permit fast total body clearance including from organs such as the liver, high tumor uptake and high tumor-to-normal-organ radiation exposure (for example, in the liver and kidneys). The immunoconjugates can be used to deliver radioisotopes including alpha and beta emitters for the treatment of tumors or cancer.

The present disclosure provides amino acid sequences (e.g., antibodies) capable of binding to glypican 3 protein (GPC3). The present disclosure relates to antigen binding fragments of GPC3 antibodies; conjugates of a GPC3 antibody, including an immunoconjugate; bispecific antibodies comprising a GPC3 antibody and related compositions and formulations. The disclosure also relates to methods of treating GPC3-related diseases, disorders and conditions, including cell proliferative diseases, such as cancer, more particularly liver cancer, using these sequences, such as GPC3 antibodies and antigen-binding fragments thereof.

The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which an anti-LAG-3 antibody is co-administered with at least one additional immunostimulatory antibody, is also provided.

Disclosed is an isolated monoclonal antibody that specifically binds human TSLP, or the antigen-binding portion thereof. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present disclosure further provides a bispecific molecule, an immunoconjugate, a CAR-immune cell, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-TSLP antibody of the disclosure.

The present disclosure relates to methods of treating metastatic non-small cell lung cancer in a patient, said methods comprising administering to the patient: (a) an anti-human PD-1 antibody or antigen binding fragment thereof; and (b) an Immunoconjugate of Formula (I) wherein: Ab is an antibody that binds to Trop-2; and n is an integer from 1 to 10.

The present invention relates to antibodies that bind AXL. The present invention relates to anti-AXL antibodies, immunoconjugates, compositions, and methods of using such anti-AXL antibodies, immunoconjugates, or compositions to treat cancer.

The present invention relates to immunoconjugates specific for human EPH receptor A5 (EphA5), methods of treatment of cancers (e.g., carcinomas including squamous cell carcinoma, and colorectal cancer) using said immunoconjugates, and related pharmaceutical compositions of said immunoconjugates.

The invention relates to an antibody specifically binding to TROP2 or an antigen binding fragment thereof. The invention also encompasses VHH antibodies or heavy chain antibodies that specifically bind to PD-L1. The invention further relates to a bispecific antibody which is constructed on the basis of the TROP2 antibody and the PD-L1 antibody and is specifically combined with the TROP2 and the PD-L1. The invention also encompasses immunoconjugates constructed based on the antibody molecules, such as antibody-conjugated drugs such as ADC. The invention further relates to a preparation method and application of the antibody molecule and the TROP2xPD-L1 targeting bispecific antibody coupling medicine.

This invention relates to anti-CD40 antibodies or antigen-binding fragments thereof that specifically recognize and weakly activate CD40 molecules in humans, cynomolgus monkeys, and mice, as well as immunoconjugates, pharmaceutical compositions, and combination products comprising said anti-CD40 antibodies or antigen-binding fragments thereof. The invention also relates to nucleic acids encoding said anti-CD40 antibodies or antigen-binding fragments thereof and host cells comprising said nucleic acids, and methods for preparing said anti-CD40 antibodies or antigen-binding fragments thereof. Furthermore, the invention relates to the use of said anti-CD40 antibodies or antigen-binding fragments thereof in the prevention or treatment of tumors or infectious diseases in subjects.

Disclosed are a new interleukin-2 (IL-2) mutant protein and the use thereof. Compared with wild-type IL-2, the IL-2 mutant protein has improved properties, such as an improved IL-2 receptor binding property and improved druggability. Also provided are a fusion protein, dimer and immunoconjugate comprising the IL-2 mutant protein, nucleic acids encoding the IL-2 mutant protein, the dimer and the immunoconjugate, and a vector and host cell comprising the nucleic acid. Further provided are methods for preparing the IL-2 mutant protein, the fusion protein, the dimer and the immunoconjugate, a pharmaceutical composition containing same, and the therapeutic use thereof.

Provided is a fusion protein, comprising a first binding domain that specifically binds a tumor-associated antigen, and a second binding domain that specifically binds a CD47 protein, wherein the second binding domain comprises a mutant of a human SIRPα variant 1. Also provided are an immunoconjugate, nucleic acid molecules, vectors, compositions, and cells related to the fusion protein and preparation methods therefor, and the uses thereof in the preparation of medicaments.

Provided are an anti-CLDN18.2 antibody or antigen-binding fragment thereof, a nucleic acid molecule encoding the same, an immunoconjugate, bispecific molecule, chimeric antigen receptor and pharmaceutical composition comprising the same. The antibody or antigen-binding fragment thereof is used for preventing and / or treating a tumor.

The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.

The present invention relates to the field of immunology and the treatment of diseases. In particular, the present invention relates to an anti-CLDN18.2 antibody or antigen-binding fragment thereof, a nucleic acid molecule encoding it, an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, and a pharmaceutical composition comprising it, and its uses for the prevention and / or treatment of a tumor.

The present application provides an anti-HER4 antibody or antigen-binding fragment thereof. The present application further provides a bispecific molecule or a multispecific molecule comprising the antibody or antigen-binding fragment thereof, an immunoconjugate, and a nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, a vector and host cell comprising the nucleic acid molecule. The present application also provides a method of preparing the antibody or antigen-binding fragment thereof, a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, and a method and use of the antibody or antigen-binding fragment thereof, or a pharmaceutical composition thereof in treating a disease, which provides a candidate specific antibody drug for the treatment and / or prevention of diseases or disorders related to HER4.

Provided is an antigen-binding protein targeting MUC1. The antigen-binding protein contains at least one CDR in a heavy chain variable region of an antibody. Further provided are a chimeric antigen receptor, immunoconjugate and pharmaceutical composition containing the antigen-binding protein, a nucleic acid encoding the antigen-binding protein, a vector containing the nucleic acid molecule, a cell containing the vector, and the use of the antigen-binding protein in the prevention and / or treatment of diseases.

Provided herein are immunoconjugate molecules containing a TNF-α polypeptide and a masking moiety capable of inhibiting and activating the TNF-α activity under suitable conditions. Also provided herein are methods for producing the immunoconjugate molecules. Finally, provided herein are the therapeutic uses of the immunoconjugate molecules due to their modulating effects on the immune system for treating diseases such as cancer and other chronic infectious diseases.

The invention provides antibodies which bind human CEACAM5 protein, as well as isolated nucleic acids and host cells comprising a sequence encoding said antibodies. The invention also provides immunoconjugates comprising said antibodies linked to a growth-inhibitory agent, and pharmaceutical compositions comprising antibodies or immunoconjugates of the invention. The invention also provides use of the antibodies, immunoconjugates and pharmaceutical compositions of the invention for the treatment of cancer or for diagnostic purposes.

The present application provides an anti-HER4 antibody or antigen-binding fragment thereof. The present application further provides a bispecific molecule or a multispecific molecule comprising the antibody or antigen-binding fragment thereof, an immunoconjugate, and a nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, a vector and host cell comprising the nucleic acid molecule. The present application also provides a method of preparing the antibody or antigen-binding fragment thereof, a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, and a method and use of the antibody or antigen-binding fragment thereof, or a pharmaceutical composition thereof in treating a disease, which provides a candidate specific antibody drug for the treatment and / or prevention of diseases or disorders related to HER4.

This invention relates to antigen-binding molecules that specifically bind to ALPPL2 and / or ALPP but not ALPL or ALPI. The invention also relates to pharmaceutical compositions, immunoconjugates, and chimeric antigen receptors comprising said antigen-binding molecules. Furthermore, the invention relates to methods for reducing the expression or activity of ALPPL2 in cancer cells, and methods for treating cancer in subjects.

The presently disclosed subject matter provides antibodies, or antigen-binding fragments thereof, that bind to L1CAM and methods of using such antibodies, or antigen-binding fragments thereof. The presently disclosed subject matter further provides immunoconjugates comprising an anti-L1CAM antibody, or antigen-binding fragment thereof, and methods of using such immunoconjugates.

Disclosed are anti-CD3 single domain antibodies and uses thereof. Also provided is a molecule, e.g., a bi-specific or multi-specific molecule, or an immunoconjugate, containing the single domain antibody. Additionally provided are nucleic acids encoding the antibody molecules, as well as vectors and host cells comprising the nucleic acids.

The invention provides immunoconjugates of Formula I comprising an antibody linked by conjugation to one or more toll-like receptor (TLR), amino-azepine derivatives. The invention also provides TLR agonist amino-azepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.

The invention provides immunoconjugates of Formula I comprising an antibody linked by conjugation to one or more toll-like receptor (TLR), amino-azepine derivatives. The invention also provides TLR agonist amino-azepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.

The present invention is directed to selected anti-PD-1 antibodies capable of binding to both cynomolgus monkey PD-1 and to human PD-1: PD-1 mAb 1, PD-1 mAb 2, PD-1 mAb 3, PD-1 mAb 4, PD-1 mAb 5, PD-1 mAb 6, PD-1 mAb 7, PD-1 mAb 8, PD-1 mAb 9, PD-1 mAb 10, PD-1 mAb 11, PD-1 mAb 12, PD-1 mAb 13, PD-1 mAb 14, or PD-1 mAb 15, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to PD-1-binding molecules that comprise PD-1 binding fragments of such anti-PD-1 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such PD-1-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of using molecules that bind PD-1 for stimulating immune responses, as well as methods of detecting PD-1.

The present invention relates to a novel interleukin-2 (IL-2) mutant protein. The present invention further provides a fusion protein and an immunoconjugate comprising the IL-2 mutant protein, a nucleic acid encoding the IL-2 mutant protein, and a vector and a host cell comprising the nucleic acid. The present invention further provides a method for preparing the IL-2 mutant protein, a pharmaceutical composition comprising the IL-2 mutant protein, and therapeutic use of the mutant protein.

The application discloses a PD-L1 binding molecule and application thereof, and relates to the technical field of monoclonal antibodies. The application also discloses a preparation method of the PD-L1 binding molecule, application of the PD-L1 binding molecule, a kit containing the PD-L1 binding molecule, an immunoconjugate and a pharmaceutical composition.